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with strong heritability, but its genetic basis is currently
unknown. Loss-of-function mutations within the filaggrin gene
are associated with atopic dermatitis and other atopic diseases;
therefore, filaggrin is a candidate gene in the etiology of peanut
allergy.
Objective: To investigate the association between filaggrin loss-
of-function mutations and peanut allergy.
Methods: Case-control study of 71 English, Dutch, and Irish
oral food challenge–positive patients with peanut allergy and
1000 non peanut-sensitized English population controls.
Replication was tested in 390 white Canadian patients with
peanut allergy (defined by food challenge, or clinical history and
skin prick test wheal to peanut >_8 mm and/or peanut-specific
IgE >_15 kUL21) and 891 white Canadian population controls.
The most prevalent filaggrin loss-of-function mutations were
assayed in each population: R501X and 2282del4 in the
Europeans, and R501X, 2282del4, R2447X, and S3247X in the
Canadians. The Fisher exact test and logistic regression were
used to test for association; covariate analysis controlled for
coexistent atopic dermatitis.
Results: Filaggrin loss-of-function mutations showed a strong
and significant association with peanut allergy in the food
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An adverse immune response to peanut ingestion may be
severe and is potentially life-threatening.1 The prevalence of IgE-
mediated peanut allergy in the United Kingdom (UK) and the
United States has increased significantly over the past decades2,3
but may now have stabilized in the UK4 and Canada.5 The prev-
alence of peanut allergy in preschool and school-age children is
approximately 1.2% to 1.6%,3-5 whereas the prevalence in US
adults is estimated to be 0.6%.3
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662 BROWN ET ALAbbreviations usedAD: Atopic dermatitisALSPAC: Avon Longitudinal Study of Parents and ChildrenFLG: FilaggrinOR: Odds ratioSPT: Skin prick testUK: United Kingdomand other siblings.7 A previously reported association with HLA
class II genes8 has not been replicated,9 and the genetic basis of
this disorder remains poorly understood.
Loss-of-function mutations in the filaggrin gene (FLG) are a
strong and significant risk factor for atopic dermatitis (AD)10 as
well as asthma in association with AD,10 allergic rhinitis,11 and
elevated IgE, indicating sensitization to certain foods.11 The
FLG gene encodes profilaggrin, an insoluble polyprotein that is
expressed in the granular layer of the epidermis and is broken
down to release filaggrinmonomers in the stratum corneum.12 Fil-
aggrin plays a key role in epithelial barrier function, but this pro-
tein is expressed in neither the bronchial airways nor the upper
gastrointestinal tract beyond the oral mucosa13 or possibly the
esophagus.14 It has been hypothesized that allergic sensitization
in the atopic state occurs via either transcutaneous or transmu-
cosal passage of allergens, a process that may be facilitated by fil-
aggrin deficiency.15,16 Experimental evidence supporting a
prominent role of epithelial barrier deficiency as a facilitating
early event in allergic priming comes from the recent analysis
of a filaggrin-deficient mouse mutant.17
In view of the strong association of FLG null mutations with
atopic disease and impaired skin barrier function, we aimed to in-
vestigate their role as a risk factor for IgE-mediated peanut
allergy.METHODS
Subjects
Seventy-one patients with peanut allergy confirmed by oral food challenge,
1000 nonsensitized controls, and the respective population controls were
collected from the white European populations of England, The Netherlands,
and Ireland, as follows:
English patients with peanut allergy. Records of thirty-five
children with peanut allergy were obtained from the Avon Longitudinal
Study of Parents and Children (ALSPAC).18 In this longitudinal birth co-
hort study, peanut allergy was defined by a suggestive clinical history
plus a positive double-blind placebo-controlled food challenge. Subjects re-
ported by parents as having flexural dermatitis at 2 or more time points (up
to a maximum of 4) between the ages of 6 and 42 months were designated
as having AD.
Dutch patients with peanut allergy. Twenty patients with
peanut allergy were recruited from pediatric allergy clinics. Peanut allergy
was defined by a positive double-blind placebo-controlled oral food challenge
test to peanut. AD was defined on the basis of a dermatologist’s examination.
Irish patients with peanut allergy. Sixteen patients with
peanut allergy were recruited from pediatric allergy clinics on the basis of a
suggestive clinical history and a positive open oral food challenge test to
peanut. AD was defined on the basis of a pediatrician’s examination or paren-
tal report.
Non–peanut-sensitized control group. ALSPAC is a lon-
gitudinal, population-based birth cohort study that originally included over
14,000 English children, as previously described.18 One thousand consecutive
non–peanut-sensitized individuals (ie, having had a negative skin prick test[SPT] result for peanut) for whom AD status was recorded were drawn
from the ALSPAC cohort as normal controls for the primary analysis. In
this control group, AD was defined in the same way as for the ALSPAC pa-
tients—that is, as having flexural dermatitis at 2 or more time points between
the ages of 6 and 42 months.
Demographic data for the food challenge–positive patients with peanut
allergy and non–peanut-sensitized controls are shown in Table I.
Population control groups. Within the ALSPAC population
birth cohort, relevant phenotype data were available for 6895 individuals
successfully typed for the 2 most common FLG null mutations (R501X and
2282del4). The 6851 individuals without peanut allergy from this collection
were used as an English population control group. One hundred Dutch popu-
lation control samples were obtained from healthy adult blood donors attend-
ing the University Medical Centre, Groningen. Irish population controls were
100 healthy adults from the population-based Trinity Biobank control
samples.Replication study
The replication of findings from the food challenge–proven patients was
tested in a larger Canadian peanut allergy case collection, as follows:
Canadian patients with peanut allergy. From an estab-
lished Canadian peanut allergy cohort,19-22 390 white patients with peanut al-
lergy were recruited between July 2008 and April 2009. They were defined as
having peanut allergy on the basis of a positive oral food challenge (n5 25) or,
in the non–food-challenged subjects, a peanut-specific IgE >_15 kUL21 (n 5
65) or a SPT wheal to peanut >_8 mm (n 5 214) or both sIgE >_15 kUL21
and SPTwheal >_8 mm (n5 86).23-25 A total of 249 (68%) of the patients de-
fined by immunologic parameters had a clinical history of anaphylaxis to pea-
nut on the basis of the consensus definition from the National Institute of
Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network,26
whereas 116 (32%) had a history strongly suggestive of type I hypersensitivity
to peanut.27 These thresholds have gained general acceptance, and in the Ca-
nadian context, it would be ethically difficult to justify the use of a food chal-
lenge in children with values exceeding these thresholds.
The clinical and immunologic data relating to the Canadian patients with
peanut allergy are summarized in Table II.
Canadian population controls. A total of 891 Canadian
controls of white ethnicity were derived from a population collection of adult
volunteers from the Toronto, Ontario, area, for whom peanut allergy status and
the presence or absence of coexistent AD were unknown.
Demographic data and clinical characteristics for the replication collection
are shown in Table III.Ethical considerations
The peanut allergy case collections were approved by the relevant local
research ethics committees, and all subjects or the subjects’ guardians gave
written informed consent. DNAwas collected and analyzed from individuals
within each of the control groups with ethical approval and written informed
consent.Genotyping for FLG loss-of-function mutations
DNA was extracted from blood or saliva samples by using standard
protocols. The FLG loss-of-function mutations that are most prevalent in the
European population were genotyped by using a previously published metho-
dology.28 R501X and 2282del4 had previously been typed in the ALSPAC co-
hort; R501X, 2282del4, R2447X, and S3247X were typed in the Dutch,
Canadian, and Irish case collections in this study.Statistical analysis
Case-control analysis to test the association
between filaggrin genotype and peanut allergy. The
Fisher exact test and logistic regression were used to test for association
TABLE I. Demographic data and clinical characteristics of 71 food challenge–positive patients with peanut allergy and a nonsensitized
control group
Patients and controls
No. of
individuals
Age (y),
range (mean)
Male sex,
n (%)
Coexistent AD,
n (%)
Patients with peanut allergy from
an English population birth cohort
35 Cohort recruited at birth
and followed up for >_7 y
19 (54.3) 16 out of 22 for whom
AD data are available
(72.7)
Dutch patients with peanut allergy 20 3-14 (7.5) 14 (70.0) 17 (85.0)
Irish patients with peanut allergy 16 1-18 (10.5) 7 (43.8) 10 (62.5)
Total patients with peanut allergy 71 Not applicable 40 (56.3) 43 (74.1)
Non–peanut-sensitized controls
from English population birth cohort
1000 Cohort recruited at birth
and followed up for >_7 y
544 (54.4) 270 (27.0)
The English population birth cohort is ALSPAC; food challenges in the English and Dutch case collections were double-blind placebo-controlled; in the Irish patients, peanut
allergy was confirmed by an open oral food challenge; % coexistent AD refers to the proportion of patients for whom AD data were available.
TABLE II. Clinical and immunologic parameters in Canadian patients with peanut allergy
Case definition n
Positive oral food challenge test to peanut 25
History of anaphylaxis to peanut26 (n 5 249) Peanut-specific IgE >_15 kU/L
SPT to peanut >_8 mm
Peanut-specific IgE >_15 kU/L and SPT to peanut >_8 mm
48
141
60
History suggestive of a type I hypersensitivity
reaction to peanut27 (n 5 116)
Peanut-specific IgE >_15 kU/L
SPT to peanut >_8 mm
Peanut-specific IgE >_15 kU/L and SPT to peanut >_8 mm
17
73
26
Total 390
A total of 390 patients with peanut allergy were drawn from an established Canadian case collection, defined as having peanut allergy on the basis of a positive oral food challenge
(n 5 25) or, in the non–food-challenged subjects, a peanut-specific IgE >_15 kUL21 (n 5 65) or an SPT wheal to peanut of >_8 mm (n 5 214) or both sIgE >_15 kUL21 and SPT
wheal >_8 mm (n 5 86).
TABLE III. Demographic data and clinical characteristics of the Canadian replication study
Patients and controls
No. of
individuals
Age (y),
range (mean)
Male sex,
n (%)
Coexistent AD,
n (%)
White Canadian patients with peanut allergy 390 0-21 (9.5) 239 (61.3) 286/383 (69.5)
White Canadian population controls 891 23-77 (57.5) 281 (31.5) Unknown
AD is defined according to parental report. Data were available in 383 Canadian patients; 266 reported AD, of whom 257 reported that a physician had made or confirmed the
diagnosis of AD; % coexistent AD refers to the proportion of patients for whom AD data were available.
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null genotype. The rationale for creating a combined null genotype for FLG is
based on biochemical and immunohistochemical studies demonstrating that
eachFLG null mutation has an equivalent biological effect.12,28 The combined
null genotype in the pooled English/ Dutch/Irish case collection used data re-
lating to the 2 mutations (R501X and 2282del4) because these were available
for all patients and the controls; the combined null genotype in the Canadian
patients and controls relates to the 4 mutations (R501X, 2282del4, R2447X,
and S3247X), and these 4 mutations were also analyzed in the subgroups of
Dutch and Irish patients with their relevant control populations.
Analysis was performed with the statistical analysis package Stata (version
9; StataCorp LP, College Station, Tex). Logistic regressionmodels the log odds
of disease as a linear function of variables encoding allele effects at the relevant
loci. A genotype variable coded as 0, 1, or 2 according to the number of mutant
alleles carried at the FLG locus was included in the regression equation.
Covariate analysis to control for coexistent AD. FLG
null mutations are strongly and significantly associated with AD,10 and AD
is more prevalent among patients with peanut allergy than in the general pop-
ulation.29,30We therefore investigated the role of coexistent AD as a risk factor
and potential confounder in the peanut-FLG association by using covariate
analysis in the food challenge–positive dataset. This analysis was not possible
in the Canadian dataset because AD status in the control population isunknown. Covariate analysis was performed by including AD as a variable
in the logistic regression equation using Stata.RESULTS
FLG null mutations are strongly and significantly
associated with peanut allergy demonstrated by
positive food challenge
Analysis of the 71 patients with peanut allergy defined by
positive oral challenge, when compared with 1000 non–peanut-
sensitized controls, showed a strong and significant association of
FLG loss-of-function mutations with peanut allergy (odds ratio
[OR], 5.3; 95% CI, 2.8-10.2; Fisher exact test, P 5 3.0 3 1026;
Table IV).
Comparison of the English (n 5 35) and Dutch (n 5 20)
patients with peanut allergy with their respective population
controls in separate case-control analyses also showed a statisti-
cally significant association betweenFLG null mutations and pea-
nut allergy in each population subgroup; analysis of the Irish
patients with peanut allergy (n 5 16) in a separate case-control
TABLE IV. Genotyping results and statistical analysis of filaggrin
loss-of-function mutations in 71 food challenge–proven patients
with peanut allergy and 1000 non–peanut-sensitized controls
Genotypes and statistical tests Patients (n) Controls (n)
No FLG mutations detected
(homozygous wild-type)
59 963
One wild-type and 1 FLG mutant allele
(heterozygous)
10 37
Two FLG loss-of-function mutations
(homozygous or compound heterozygous)
2 0
Total 71 1000
Proportion of individuals carrying FLG
loss-of-function mutations (%)
16.9 3.7
Fisher exact test P 5 3.0 3 1026
OR (95% CI) 5.3 (2.8-10.2)
This combined population dataset relates to the 2 most prevalent FLG loss-of-function
mutations (R501X and 2282del4) in English (n 5 35), Dutch (n 5 20), and Irish (n 5
16) patients with peanut allergy demonstrated by oral food challenge. The
designations homozygous wild-type, heterozygous, and 2 null mutations represent the
combined null genotype results for the 2 available mutations; individuals with 2 null
mutations may be homozygous for an FLG null allele or compound heterozygous,
having 2 different FLG null alleles.
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small number of patients (Table V).FLG null mutations are associated with peanut
allergy in a Canadian case-control study
Table VI summarizes the genotype data and association analy-
sis for the Canadian patients and controls. The highly significant
association is replicated (P5 5.43 1025) with an estimated OR
of 1.9 (95% CI, 1.2-2.6).Association between FLG null mutations and
peanut allergy is not solely attributable to
coexistent AD
Covariate analysis using both AD and FLG as predictors in the
logistic regression model demonstrated the strong association of
atopic eczema with peanut allergy in the 71 food challenge–pos-
itive patients, with an OR of 7.4 (95% CI, 4.1-13.7). However, in
these same patients, having controlled for AD, the residual OR for
FLG in association with peanut allergy was 3.8 (95% CI, 1.7-8.3;
P 5 .0008).DISCUSSION
The major known risk factors for IgE-mediated peanut allergy
are family history of the disease and coexistent atopy.29 However,
despite the clinical importance of peanut allergy and its strong
heritability, no significant genetic risk factors have previously
been confirmed by replication studies. Taken together, our exper-
imental data from 4 populations of European origin demonstrate a
strong and significant association of loss-of-function mutations
within the FLG gene with clinically significant peanut allergy.
Furthermore, we have confirmed, by using covariate analysis in
the food challenge–positive patients, that this association does
not simply represent a coassociation with AD. The association be-
tween FLG and peanut allergy is not fully accounted for by con-
founding with coexistent AD, because the statistically significantassociation of the combined FLG null genotype with peanut
allergy persists even after controlling for AD (P 5 .0008).
The differing case collections chosen for this genetic epide-
miologic study offer complementary insights into the possible
link between FLG genotype and peanut allergy. The white
European dataset had a positive result to food challenge testing
that was double-blind and placebo-controlled in the English
(n 5 35) and Dutch (n 5 20) patients and an open challenge in
the Irish (n 5 16) patients. Double-blind placebo-controlled
oral food challenge is the gold standard in a research setting,
but open or single-blind challenges are more standard clinical
practice,2,30 particularly in children. The ALSPAC cohort is a
large, unselected population birth cohort in which data have
been collected on a prospective basis, providing the opportunity
for a case-control study in which the controls are appropriately
matched to patients and in which data on coexistent AD have
been collected. The Canadian collection of patients with peanut
allergy, however, provides a much greater statistical power be-
cause of the larger number of individuals with peanut allergy
available for analysis. There is a striking age difference between
the Canadian patients and the control population. However, be-
cause AD does not affect survival pattern, this study design would
not be predicted to affect the findings or interpretation of data.
The higher OR of disease in the combined English, Dutch, and
Irish dataset compared with the Canadian study may be explained
by the use of a hypernormal (nonsensitized) English control
population, whereas the Canadian population controls would
include individuals with current or previous peanut sensitization
or allergy, resulting in a lower OR. However, it is interesting to
note that the estimated OR is 3.2 to 3.5 (95% CI, 1.0-11.7) in each
of the population subgroups when they are compared with their
respective unselected population controls (Table V). Alterna-
tively, or in addition, there may be unidentified FLG null muta-
tions within the white Canadian population that have not been
included in the statistical analysis, therefore possibly leading to
an underestimation of the FLG association. We limited our anal-
ysis in these large studies to the 2 or 4 most common FLG muta-
tions and are therefore likely to have underestimated the total
contribution of FLG null alleles to this disease association. We
limited our analyses to these selected mutations because the
FLG gene is large and its DNA sequence is highly repetitive, mak-
ing genotyping technically difficult.12
It would be interesting and informative to dissect further the
association ofFLG statuswithAD, food sensitization, and allergy.
However, the separation of AD, food allergy, and food sensitiza-
tion data is complex and challenging because these phenotypes
show considerable overlap. Furthermore, the definition of peanut
allergy in the Canadian patients necessarily includes peanut sen-
sitization data, and our analysis is limited because data on AD and
food allergy phenotypes are not available for the Canadian control
population. The analysis ofFLG genotype and peanut allergywith
AD as a confounding factor was therefore limited to the food chal-
lenge–positive patients and nonsensitized controls.
The estimated OR for FLG as a risk factor for peanut allergy is
5.3 (95% CI, 2.8-10.2) in the pooled analysis of English/Dutch/
Irish food challenge–positive patients for whom 2 FLG loss-of-
function mutations were assessed; the equivalent OR is 1.9
(95% CI, 1.4-2.6) in the Canadian collection (Table VI), 3.5
(95% CI, 1.1-11.4) in the Dutch collection, and 3.3 (95% CI,
1.0-11.7) in the Irish collection (Table V), for whom 4 FLG
null mutations were assessed. A total of over 20 FLG null
TABLE V. Genotyping results and statistical analysis of filaggrin loss-of-function mutations in patients with peanut allergy and
matched controls from English, Dutch, and Irish populations
Genotypes and statistical tests
English (ALSPAC) Dutch Irish
Patients (n) Controls (n) Patients (n) Controls (n) Patients (n) Controls (n)
No FLG mutations detected (homozygous wild-type) 28 6368 17 95 13 93
One wild-type and 1 FLG mutant allele (heterozygous) 7 480 1 5 2 7
Two FLG loss-of-function mutations
(homozygous or compound heterozygous)
0 3 2 0 1 0
Total 35 6851 20 100 16 100
Proportion of individuals carrying FLG
loss-of-function mutations (%)
20.0 7.1 15.0 5.0 18.8 7.0
Fisher exact test P 5 .0251 P 5 .0335 P 5 .0640
OR (95% CI) 3.2 (1.4-7.2) 3.5 (1.1-11.4) 3.3 (1.0-11.7)
The ALSPAC is a longitudinal, population-based birth cohort study.18 This English population was screened for the 2 most common FLG null mutations (R501X and 2282del4). In
the Dutch and Irish patients and controls, the 4 most prevalent FLG loss-of-function mutations were assayed (R501X, 2282del4, R2447X, and S3247X). The designations
homozygous wild-type, heterozygous, and 2 null mutations represent the combined null genotype results for the available mutations in each population.
TABLE VI. Genotyping results and statistical analysis of filaggrin
loss-of-function mutations in a case-control study in the
Canadian population
Genotypes and statistical tests Patients (n) Controls (n)
No FLG mutations detected
(homozygous wild-type)
315 793
One wild-type and 1 FLG mutant
allele (heterozygous)
66 94
Two FLG loss-of-function mutations
(homozygous or compound
heterozygous)
9 4
Total 390 891
Proportion of individuals carrying FLG
loss-of-function mutations (%)
19.2 11.0
Fisher exact test P 5 5.4 3 1025
OR (95% CI) 1.9 (1.4-2.6)
Patients and controls were screened for the 4 most prevalent FLG loss-of-function
mutations (R501X, 2282del4, R2447X, and S3247X). The designations homozygous
wild-type, heterozygous, and 2 null mutations represent the combined null genotype
results for the 4 available mutations.
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pean ancestry. In the Irish population, themost intensively studied
white European population with respect to FLG, R501X and
2282del4 together represent about 66% of the FLG mutations;
adding R2447X and S3247X covers about 95% of the known
FLG mutations.
The prevalence of food challenge–positive peanut allergy
within this subset of the 1989 to 1990 ALSPAC birth cohort is
0.6%, consistent with other published data.2 The proportion of
these patients carrying 1 or more FLG null mutations (associated
with an estimated OR of 3.2) is 20.0% (Table V). Similarly, in the
Canadian study, 19.2% of the patients with peanut allergy carry
1 or more FLG null mutations, with an estimated OR of 1.9
(Table VI). These data demonstrate the striking contribution of
a single gene in the etiology of a complex trait resulting frommul-
tiple genetic and environmental effects.
The mechanisms by which filaggrin deficiency in the skin may
lead to AD and other atopic disorders have been debated
extensively.15,31,32 It is proposed that impairment of the epidermal
barrier allows the penetration of allergens and irritants, resulting
in local inflammation as well as a systemic atopic response. There
is experimental evidence in support of this hypothesis frommouse
models17,33-35 as well as clinical epidemiologic studies showing
that FLG null mutations are a risk factor for asthma only in the
subtype of asthma that is associated with AD.10 Similarly, it has
been suggested that peanut sensitization may result from transcu-
taneous exposure to peanut allergens in the environment36 or in
topical preparations,29 particularly because early-onset AD is a
risk factor for peanut allergy.29 This contrasts with the oral route
of exposure, which is thought to be tolerogenic.37 However, intes-
tinal permeability is known to be increased amongst some pa-
tients with AD,38 and it has been suggested that intestinal
permeability may be an additional route of allergen penetration
in peanut allergy and other food allergies.39 The extent and func-
tional significance of filaggrin expression in the gastrointestinal
tract below the oral mucosa is currently unknown but warrants
further investigation. This study focused on the association be-
tween FLG loss-of-function mutations and peanut allergy; the
possibility of association with other food allergies has not been
addressed and also warrants further investigation. One previous
study of FLG genotype and sensitization to foods was conducted
as a subgroup analysis within a German cohort study on asthmarisk.40 This analysis showed a strong synergistic interaction be-
tween the FLG-null alleles and early food sensitization in the dis-
ease transition from eczema to asthma (relative excess risk, 2.64)
but no significant association of FLG status with food sensitiza-
tion per se in 185 children with AD. Although the subgroup sam-
ple size was rather small, these contrasting data may reflect
differences in the pathogenesis of food sensitization versus food
allergy as well as possible differences in the pathogenesis of al-
lergy to different foods.
The well recognized strong association of AD with peanut
allergy is demonstrated in the results of covariate analysis, in
which eczema shows an estimated OR of 7.4 compared with the
FLG estimated OR (after accounting for AD) of 3.8. Hence, AD is
a stronger independent risk factor for peanut allergy thanFLG null
mutations. However, it is interesting and noteworthy that the FLG
genotype effect is not solely accounted for by a coassociation with
AD, a finding that contributes to the debate outlined regarding the
routes and mechanisms of allergic sensitization. It is possible that
the association ofFLG loss-of-functionmutations persists because
of incorrect assignment of patients with AD to the non-AD sub-
group (ie, incomplete case ascertainment of AD on the basis of
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titis reported by parents on at least 2 occasions (in the ALSPAC co-
hort), could possibly have failed to include children with mild,
localized, or transient disease in the AD case collection. However,
the high prevalence of coexistent AD in the ALSPAC cohort, at
27.1% in subjects without peanut allergy (Table III) and 27.6%
in the cohort as a whole, in comparison with published UK stud-
ies,41 suggests that few patients have been missed by this case def-
inition. Absence of established AD according to the case
definitions used in these studies does not preclude a significant ep-
idermal barrier defect in filaggrin-deficient individuals. Murine
models of filaggrin deficiency have shown enhanced percutaneous
allergen sensitization in 3 studies.17,34,35 These mice appear to
have an inherent epithelial barrier defect that facilitates allergen
priming in the absence of clinical evidence of cutaneous
inflammation.
Here we have shown that FLG mutations confer a risk for pea-
nut allergy in the absence of clinical evidence of AD. In contrast,
although FLG null alleles confer a significant risk of asthma, with
a reproducible OR of 1.8, this effect is confined to those with pre-
existent or coexistent AD.10 The mechanistic pathways through
which FLG null alleles contribute risk to these related but distinct
atopic phenotypes are as yet unclear.
In conclusion, FLG null mutations not only represent a highly
significant genetic risk factor for AD but also are the single
most significant genetic risk for peanut allergy that has been iden-
tified to date. The robustness of this association is demonstrated
by replication within 3 populations— English, Dutch, and
Canadian—plus an association close to significance in an Irish
collection. The association of FLGmutations with peanut allergy
adds further insight into the pathogenesis of the atopic state
and the critical role of epithelial barrier function in health and
disease.
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University.
Key messages
d Loss-of-function variants in the filaggrin gene are
strongly and significantly associated with peanut allergy.
d The association of filaggrin mutations with peanut allergy
cannot fully be accounted for by the confounding effect of
coexistent AD.
d Filaggrin mutations are a novel risk factor for IgE-
mediated peanut allergy, indicating a role for epithelial
barrier dysfunction in the pathogenesis of this disease.
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